Help Shape the Future of Myeloma Care, Share Your Voice in a 10-Minute Survey. Be part of a patient-centered study led by Dr. C. Ola Landgren (University of Miami) exploring how multiple myeloma patients view MRD negativity as a marker of treatment success, its role in treatment success for access to new therapies, and its role in clinical trial design.  Your insights are vital to advancing care and making sure the patient's perspective is heard in research and regulatory decisions. Every voice in our community matters, and your participation could make a real difference in how we support blood cancer patients! Ready to contribute? Click here to take the survey: https://healthtree.org/myeloma/curehub/private/research/RxT3lYUKSbJuAqArLtdM?utm_source=social+media&utm_medium=connect&utm_campaign=mrdperception&utm_content=general If you’d like to learn more about MRD, you can check out an article published in March 2025. https://htree.org/MDRarticle2025survey